MX2013012862A - Composiciones para inhibir la activacion del complemento dependiente de la masp-2. - Google Patents
Composiciones para inhibir la activacion del complemento dependiente de la masp-2.Info
- Publication number
- MX2013012862A MX2013012862A MX2013012862A MX2013012862A MX2013012862A MX 2013012862 A MX2013012862 A MX 2013012862A MX 2013012862 A MX2013012862 A MX 2013012862A MX 2013012862 A MX2013012862 A MX 2013012862A MX 2013012862 A MX2013012862 A MX 2013012862A
- Authority
- MX
- Mexico
- Prior art keywords
- cdr
- convertase
- alternative pathway
- masp
- chain variable
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title abstract 3
- 230000001419 dependent effect Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000000295 complement effect Effects 0.000 title 1
- 108010003529 Alternative Pathway Complement C3 Convertase Proteins 0.000 abstract 4
- 108010005642 Properdin Proteins 0.000 abstract 2
- 102100038567 Properdin Human genes 0.000 abstract 2
- 108010083822 Alternative Pathway Complement C5 Convertase Proteins 0.000 abstract 1
- 108090000056 Complement factor B Proteins 0.000 abstract 1
- 102000003712 Complement factor B Human genes 0.000 abstract 1
- 101001056015 Homo sapiens Mannan-binding lectin serine protease 2 Proteins 0.000 abstract 1
- 101710117460 Mannan-binding lectin serine protease 2 Proteins 0.000 abstract 1
- 102100026046 Mannan-binding lectin serine protease 2 Human genes 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000024203 complement activation Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 102000054960 human MASP2 Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21104—Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se relaciona con anticuerpos inhibidores de anti-MASP-2 y composiciones que comprenden dichos anticuerpos para su uso en la inhibición de los efectos secundarios de la activación del complemento dependiente de la MASP-2. EN un aspecto, la invención proporciona un anticuerpo monoclonal aislado humano, o un fragmento de unión a antígeno del mismo, que se une a la MASP-2 humana, comprendiendo: i) una región variable de cadena pesada que comprende secuencias de CDR-H1, CDR-H2 y CDR-H3, y (ii) una región variable de cadena ligera que comprende CDR-L1, CDR-L2 y CDR-L3, en donde la región variable de la secuencia de CDR-H3 de cadena pesada comprende una secuencia de aminoácidos establecida con factor B en la formación de C3 convertasa de la vía alternativa (C3bBb) adicional. La C3 convertasa de la vía alternativa es estabilizada por la unión de la properdina. La properdina extiende la vida media de la C3 convertasa de la vía alternativa de seis a diez veces. La adición de C3b a la C3 convertasa de la vía alternativa lleva a la formación de la C5 convertasa de la vía alternativa.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161482567P | 2011-05-04 | 2011-05-04 | |
| PCT/US2012/036509 WO2012151481A1 (en) | 2011-05-04 | 2012-05-04 | Compositions for inhibiting masp-2 dependent complement acitivation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013012862A true MX2013012862A (es) | 2013-12-02 |
| MX347691B MX347691B (es) | 2017-05-09 |
Family
ID=47090380
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013012862A MX347691B (es) | 2011-05-04 | 2012-05-04 | Composiciones para inhibir la activacion del complemento dependiente de la masp-2. |
| MX2017006060A MX361175B (es) | 2011-05-04 | 2012-05-04 | Composiciones para inhibir la activación del complemento dependiente de la masp-2. |
| MX2018014714A MX2018014714A (es) | 2011-05-04 | 2013-11-04 | Composiciones para inhibir la activacion del complemento dependiente de la masp-2. |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017006060A MX361175B (es) | 2011-05-04 | 2012-05-04 | Composiciones para inhibir la activación del complemento dependiente de la masp-2. |
| MX2018014714A MX2018014714A (es) | 2011-05-04 | 2013-11-04 | Composiciones para inhibir la activacion del complemento dependiente de la masp-2. |
Country Status (26)
| Country | Link |
|---|---|
| US (6) | US9011860B2 (es) |
| EP (2) | EP3725811A3 (es) |
| JP (6) | JP5891298B2 (es) |
| KR (3) | KR102024016B1 (es) |
| CN (2) | CN107011443B (es) |
| AU (1) | AU2012250627B2 (es) |
| BR (1) | BR112013028429B1 (es) |
| CA (3) | CA3131223C (es) |
| CL (1) | CL2013003140A1 (es) |
| CY (1) | CY1123212T1 (es) |
| DK (1) | DK2704743T3 (es) |
| ES (1) | ES2795667T3 (es) |
| HR (1) | HRP20200887T1 (es) |
| HU (1) | HUE049154T2 (es) |
| IL (4) | IL229208B (es) |
| LT (1) | LT2704743T (es) |
| ME (1) | ME03755B (es) |
| MX (3) | MX347691B (es) |
| PL (1) | PL2704743T3 (es) |
| PT (1) | PT2704743T (es) |
| RS (1) | RS60541B1 (es) |
| RU (3) | RU2636038C2 (es) |
| SI (1) | SI2704743T1 (es) |
| SM (1) | SMT202000294T1 (es) |
| WO (1) | WO2012151481A1 (es) |
| ZA (1) | ZA201308943B (es) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2202245T3 (en) | 2007-09-26 | 2016-11-21 | Chugai Pharmaceutical Co Ltd | A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR |
| JP4954326B2 (ja) | 2008-04-11 | 2012-06-13 | 中外製薬株式会社 | 複数分子の抗原に繰り返し結合する抗原結合分子 |
| SG190727A1 (en) | 2010-11-30 | 2013-07-31 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
| CA3237802A1 (en) | 2011-04-08 | 2012-10-11 | Omeros Corporation | Methods for treating conditions associated with masp-2 dependent complement activation |
| US9644035B2 (en) | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| KR102024016B1 (ko) * | 2011-05-04 | 2019-11-04 | 오메로스 코포레이션 | Masp-2 의존적 보체 활성화를 억제하는 조성물 |
| EP2889376A4 (en) | 2012-08-24 | 2016-11-02 | Chugai Pharmaceutical Co Ltd | ANTIBODIES Fc SPECIFIC TO FCTRII OF MOUSE |
| EP2912065A4 (en) | 2012-10-25 | 2016-10-19 | True North Therapeutics Inc | ANTI COMPLEMENT C1S ANTIBODIES AND USES THEREOF |
| GB2509260B (en) | 2012-11-02 | 2016-05-04 | True North Therapeutics Inc | Anti-complement C1s antibodies and uses thereof |
| US20140363433A1 (en) | 2013-03-15 | 2014-12-11 | Omeros Corporation | Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same |
| WO2014144542A2 (en) * | 2013-03-15 | 2014-09-18 | Omeros Corporation | Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same |
| CN113621057A (zh) | 2013-04-02 | 2021-11-09 | 中外制药株式会社 | Fc区变体 |
| AU2014337047B2 (en) * | 2013-10-17 | 2020-03-12 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| AR103161A1 (es) | 2014-12-19 | 2017-04-19 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso |
| EA201791754A1 (ru) | 2015-02-05 | 2019-01-31 | Чугаи Сейяку Кабусики Кайся | АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ |
| SG11201707886WA (en) | 2015-04-06 | 2017-10-30 | True North Therapeutics Inc | Humanized anti-c1s antibodies and methods of use thereof |
| CN106699888B (zh) | 2015-07-28 | 2020-11-06 | 上海昀怡健康科技发展有限公司 | 一种pd-1抗体及其制备方法和应用 |
| MD4685C1 (ro) | 2015-11-09 | 2020-12-31 | Omeros Corporation | Metodă de tratament al stărilor asociate cu activarea complementului dependentă de MASP-2 |
| EP3394098A4 (en) | 2015-12-25 | 2019-11-13 | Chugai Seiyaku Kabushiki Kaisha | ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE |
| SG10202001580SA (en) | 2016-01-05 | 2020-04-29 | Univ Leicester | Methods for inhibiting fibrosis in a subject in need thereof |
| CN109152834A (zh) | 2016-03-31 | 2019-01-04 | 奥默罗斯公司 | 抑制有需要的受试者的血管发生的方法 |
| JOP20170154B1 (ar) * | 2016-08-01 | 2023-03-28 | Omeros Corp | تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة |
| CA3026050A1 (en) | 2016-08-05 | 2018-02-08 | Chugai Seiyaku Kabushiki Kaisha | Composition for prophylaxis or treatment of il-8 related diseases |
| JOP20170170B1 (ar) * | 2016-08-31 | 2022-09-15 | Omeros Corp | صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق |
| SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
| JOP20190068A1 (ar) * | 2016-10-13 | 2019-04-01 | Omeros Corp | طرق لتقليل البول البروتيني في خاضع بشري يعاني من الاعتلال الكلوي a الناتج عن الجلوبيولين المناعي |
| TWI881481B (zh) * | 2017-08-15 | 2025-04-21 | 美商歐米諾斯公司 | 用於治療和／或預防與造血幹細胞移植有關的移植物抗宿主病和／或瀰漫性肺泡出血和／或靜脈閉塞性病的方法 |
| JP2020531523A (ja) * | 2017-08-25 | 2020-11-05 | オメロス コーポレーション | 高度に濃縮された低粘度のｍａｓｐ−２阻害抗体製剤、キット、および非定型溶血性症候群に罹患した対象の治療方法 |
| CN116327926A (zh) | 2018-03-15 | 2023-06-27 | 中外制药株式会社 | 对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法 |
| IL311042A (en) | 2018-05-29 | 2024-04-01 | Omeros Corp | MASP-2 inhibitors and methods of use |
| US11584714B2 (en) | 2018-05-29 | 2023-02-21 | Omeros Corporation | MASP-2 inhibitors and methods of use |
| HUE068993T2 (hu) * | 2018-12-13 | 2025-02-28 | argenx BV | Humán C2B komplementfaktor elleni antitestek és alkalmazási eljárások |
| MX2022006334A (es) * | 2019-11-26 | 2022-06-22 | Omeros Corp | Metodos para tratar y/o prevenir el sindrome de neumonia idiopatica (ips) y/o el sindrome de fuga capilar (cls) y/o el sindrome de injerto (es) y/o la sobrecarga de fluidos (fo) asociados con el trasplante de celulas madre hematopoyeticas. |
| WO2021113686A1 (en) | 2019-12-04 | 2021-06-10 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| AU2020397894B2 (en) | 2019-12-04 | 2025-02-20 | Omeros Corporation | MASP-2 inhibitors and methods of use |
| AU2020395306B2 (en) | 2019-12-04 | 2025-04-24 | Omeros Corporation | MASP-2 inhibitors and methods of use |
| BR112022010895A2 (pt) | 2019-12-04 | 2022-09-06 | Omeros Corp | Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado à serina protease-2 associada à lectina de ligação ao manan |
| TWI867422B (zh) | 2020-03-06 | 2024-12-21 | 美商奥默羅斯公司 | 用於治療和/或預防流感病毒誘導的急性呼吸窘迫症候群、肺炎或者流感病毒感染的一些其它肺部表現的抑制masp-2的方法 |
| CN120173119A (zh) | 2020-12-16 | 2025-06-20 | 康诺亚生物医药科技（成都）有限公司 | 一种补体抑制剂的开发和应用 |
| US20220308056A1 (en) * | 2021-02-05 | 2022-09-29 | Omeros Corporation | Biomarker for assessing the risk of developing acute covid-19 and post-acute covid-19 |
| CN115215937B (zh) | 2021-04-15 | 2023-05-26 | 上海麦济生物技术有限公司 | 抗人masp-2抗体及其制备方法和应用 |
| US20240209114A1 (en) | 2021-04-25 | 2024-06-27 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anti-masp2 antibody, antigen-binding fragment thereof and medical use thereof |
| BR112023025596A2 (pt) * | 2021-06-08 | 2024-02-27 | Jiangxi Jemincare Group Co Ltd | Anticorpo anti-masp-2 e uso do mesmo |
| CN117616042A (zh) * | 2021-06-30 | 2024-02-27 | 苏州创胜医药集团有限公司 | 新的抗masp-2抗体 |
| AU2022405100A1 (en) | 2021-12-10 | 2024-07-25 | Omeros Corporation | Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof |
| CN116615544A (zh) * | 2021-12-10 | 2023-08-18 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别masp2的抗体及其应用 |
| CN116284412A (zh) * | 2021-12-21 | 2023-06-23 | 沈阳三生制药有限责任公司 | 一种抗masp-2抗体及其制备方法与用途 |
| WO2023174039A1 (en) * | 2022-03-18 | 2023-09-21 | Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. | Masp-2-targetting antibodies and uses thereof |
| US20240228499A1 (en) | 2022-11-30 | 2024-07-11 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| US12216123B2 (en) | 2023-04-25 | 2025-02-04 | Nuvance Health | Extracellular vesicle derived MASP-2 directed cancer treatment methods |
| US20250122225A1 (en) | 2023-10-06 | 2025-04-17 | Omeros Corporation | Masp-2 inhibitors and methods of use |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5211657A (en) | 1988-11-07 | 1993-05-18 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides |
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
| JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
| US5856121A (en) | 1994-02-24 | 1999-01-05 | Case Western Reserve University | Growth arrest homebox gene |
| JPH07238100A (ja) | 1994-02-25 | 1995-09-12 | Sumitomo Electric Ind Ltd | ヒトのｍａｓｐに対するモノクローナル抗体 |
| US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| JPH10510540A (ja) | 1994-12-12 | 1998-10-13 | オメロス メディカル システムズ，インコーポレーテッド | 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法 |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| US6969601B2 (en) | 1997-04-03 | 2005-11-29 | Jensenius Jens Chr | MASP-2, a complement-fixing enzyme, and uses for it |
| CA2347734A1 (en) | 1998-12-15 | 2000-06-22 | Brigham And Women's Hospital, Inc. | Methods and products for regulating lectin complement pathway associated complement activation |
| EP1797869A3 (en) | 1999-07-21 | 2008-07-23 | Omeros Corporation | Solutions and methods for inhibition of pain, inflammation and cartilage degradation |
| US20010051754A1 (en) | 1999-08-03 | 2001-12-13 | Daria N. Lissy | Plural stage toluene disproportionation process minimizing ethylbenzene |
| JP2003525061A (ja) * | 2000-03-01 | 2003-08-26 | メディミューン，インコーポレイテッド | 高効力組換え抗体およびその産生法 |
| SG98393A1 (en) | 2000-05-19 | 2003-09-19 | Inst Materials Research & Eng | Injectable drug delivery systems with cyclodextrin-polymer based hydrogels |
| US7112414B2 (en) * | 2000-07-13 | 2006-09-26 | Jens Christian Jensenius | Masp-2, a complement-fixing enzyme, and uses for it |
| EP1300419B1 (en) * | 2001-10-05 | 2007-06-13 | Affimed Therapeutics AG | Antibody of human origin for inhibiting thrombocyte aggregation |
| ES2645563T3 (es) * | 2001-11-30 | 2017-12-05 | Amgen Fremont Inc. | Animales transgénicos que portan genes de cadena ligera de Ig humana |
| AU2003212898B2 (en) | 2002-02-01 | 2008-10-02 | Omeros Corporation | Compositions and methods for systemic inhibition of cartilage degradation |
| ES2601143T3 (es) | 2002-07-19 | 2017-02-14 | Omeros Corporation | Copolímeros tribloque biodegradables, métodos de síntesis de los mismos, e hidrogeles y biomateriales preparados a partir de los mismos |
| EP1598419A1 (en) | 2003-02-28 | 2005-11-23 | Mitsubishi Pharma Corporation | Monoclonal antibody, gene encoding the same, hybridoma, medicinal composition and diagnostic reagent |
| HUE024996T2 (en) * | 2003-05-12 | 2016-01-28 | Helion Biotech Aps | Anti-MASP-2 antibodies |
| EP3047858A1 (en) | 2004-06-10 | 2016-07-27 | Omeros Corporation | Methods for treating conditions associated with masp-2 dependent complement activation |
| US8840893B2 (en) | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US20060018896A1 (en) | 2004-06-10 | 2006-01-26 | University Of Leicester | Methods for treating conditions associated with lectin-dependent complement activation |
| US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| GB0412966D0 (en) | 2004-06-10 | 2004-07-14 | Univ Leicester | Genetically modified non-human mammals and cells |
| CN102264763B (zh) * | 2008-09-19 | 2016-04-27 | 米迪缪尼有限公司 | 定向于dll4的抗体及其用途 |
| US9403904B2 (en) * | 2008-11-07 | 2016-08-02 | Fabrus, Inc. | Anti-DLL4 antibodies and uses thereof |
| SI2488203T1 (sl) | 2009-10-16 | 2017-07-31 | Omeros Corporation | Metode za zdravljenje diseminirane intravaskularne koagulacije z inhibiranjem aktivacije masp-2 odvisnega komplementa |
| KR102024016B1 (ko) * | 2011-05-04 | 2019-11-04 | 오메로스 코포레이션 | Masp-2 의존적 보체 활성화를 억제하는 조성물 |
| WO2013180834A2 (en) * | 2012-04-06 | 2013-12-05 | Omeros Corporation | Compositions and methods of inhibting masp-1 and/or masp-3 for the treatment of paroxysmal nocturnal hemoglobinuria |
-
2012
- 2012-05-04 KR KR1020187021028A patent/KR102024016B1/ko active Active
- 2012-05-04 PT PT127793479T patent/PT2704743T/pt unknown
- 2012-05-04 LT LTEP12779347.9T patent/LT2704743T/lt unknown
- 2012-05-04 JP JP2014509474A patent/JP5891298B2/ja active Active
- 2012-05-04 AU AU2012250627A patent/AU2012250627B2/en active Active
- 2012-05-04 US US13/464,334 patent/US9011860B2/en active Active
- 2012-05-04 SM SM20200294T patent/SMT202000294T1/it unknown
- 2012-05-04 WO PCT/US2012/036509 patent/WO2012151481A1/en active Application Filing
- 2012-05-04 CA CA3131223A patent/CA3131223C/en active Active
- 2012-05-04 ME MEP-2020-121A patent/ME03755B/me unknown
- 2012-05-04 SI SI201231793T patent/SI2704743T1/sl unknown
- 2012-05-04 RU RU2013153527A patent/RU2636038C2/ru active
- 2012-05-04 CA CA3025762A patent/CA3025762C/en active Active
- 2012-05-04 CN CN201710201126.9A patent/CN107011443B/zh active Active
- 2012-05-04 EP EP19215429.2A patent/EP3725811A3/en active Pending
- 2012-05-04 HU HUE12779347A patent/HUE049154T2/hu unknown
- 2012-05-04 RS RS20200685A patent/RS60541B1/sr unknown
- 2012-05-04 HR HRP20200887TT patent/HRP20200887T1/hr unknown
- 2012-05-04 CA CA2832871A patent/CA2832871C/en active Active
- 2012-05-04 PL PL12779347T patent/PL2704743T3/pl unknown
- 2012-05-04 KR KR1020167018831A patent/KR101882830B1/ko active Active
- 2012-05-04 BR BR112013028429-3A patent/BR112013028429B1/pt active IP Right Grant
- 2012-05-04 DK DK12779347.9T patent/DK2704743T3/da active
- 2012-05-04 MX MX2013012862A patent/MX347691B/es active IP Right Grant
- 2012-05-04 MX MX2017006060A patent/MX361175B/es unknown
- 2012-05-04 KR KR1020137032078A patent/KR101641057B1/ko active Active
- 2012-05-04 EP EP12779347.9A patent/EP2704743B1/en active Active
- 2012-05-04 ES ES12779347T patent/ES2795667T3/es active Active
- 2012-05-04 CN CN201280032866.XA patent/CN103687620B/zh active Active
- 2012-11-03 IL IL229208A patent/IL229208B/en active IP Right Grant
-
2013
- 2013-10-30 CL CL2013003140A patent/CL2013003140A1/es unknown
- 2013-11-03 IL IL229208A patent/IL229208A0/en unknown
- 2013-11-04 MX MX2018014714A patent/MX2018014714A/es unknown
- 2013-11-27 ZA ZA2013/08943A patent/ZA201308943B/en unknown
-
2015
- 2015-03-17 US US14/660,040 patent/US9475885B2/en active Active
- 2015-09-09 JP JP2015177337A patent/JP6352226B2/ja active Active
-
2016
- 2016-09-13 US US15/263,876 patent/US10047165B2/en active Active
-
2017
- 2017-10-31 RU RU2017137872A patent/RU2725958C2/ru active
-
2018
- 2018-04-04 JP JP2018072245A patent/JP6669800B2/ja active Active
- 2018-07-13 US US16/034,896 patent/US10683367B2/en active Active
-
2019
- 2019-05-20 IL IL266756A patent/IL266756B/en unknown
-
2020
- 2020-02-27 JP JP2020031661A patent/JP2020097630A/ja not_active Withdrawn
- 2020-04-24 US US16/857,558 patent/US11613589B2/en active Active
- 2020-06-10 CY CY20201100525T patent/CY1123212T1/el unknown
- 2020-06-22 RU RU2020120539A patent/RU2020120539A/ru unknown
-
2021
- 2021-08-10 IL IL285522A patent/IL285522A/en unknown
-
2022
- 2022-09-02 JP JP2022139872A patent/JP2022172275A/ja not_active Withdrawn
-
2023
- 2023-02-13 US US18/168,192 patent/US20240092938A1/en active Pending
-
2024
- 2024-09-10 JP JP2024156933A patent/JP2024170616A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018014714A (es) | Composiciones para inhibir la activacion del complemento dependiente de la masp-2. | |
| AU2016204274A1 (en) | Antibodies that bind to OX40 and their uses | |
| AU2018256487A1 (en) | Antibodies that bind to TL1A and their uses | |
| CO2018004532A2 (es) | Anticuerpos anti-cd19 humano con alta afinidad | |
| EA201190132A1 (ru) | Гуманизированные антитела, связывающиеся с cd19, и их применение | |
| AR065506A1 (es) | Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades | |
| UA108466C2 (en) | Antibody antagonises c-Met | |
| NZ585559A (en) | Humanized antibodies against tl1a | |
| NZ603045A (en) | Tnf-alpha binding proteins | |
| NZ599959A (en) | Novel antibodies inhibiting c-met dimerization, and uses thereof | |
| NZ629829A (en) | Anti-c5a antibodies and methods for using the antibodies | |
| PE20120343A1 (es) | Anticuerpo anti-cmet que comprende una region bisagra | |
| AR080501A1 (es) | Anticuerpos anti factor determinante antigenico de la muerte programada 1 (anti-pd1) | |
| RU2014143785A (ru) | Фармацевтическая композиция для лечения и/или предотвращения рака печени | |
| NZ602892A (en) | Antibodies that bind human cd27 and uses thereof | |
| RU2014143784A (ru) | Фармацевтическая композиция для лечения и/или предотвращения рака желчного пузыря | |
| RS53405B (en) | Humanized anti cxcr4 antibodies for the treatment of cancer | |
| CO6480962A2 (es) | Anticuerpos anti-vegf y sus usos | |
| NZ595687A (en) | Anti-tnf-alpha antibodies and their uses | |
| WO2012109280A3 (en) | Apoe immunotherapy | |
| AR078796A1 (es) | Composiciones y metodos para tratar trastornos inflamatorios | |
| NZ596712A (en) | Anti cxcr4 antibodies for the treatment of hiv | |
| NZ705653A (en) | Novel antibody for the diagnosis and/or prognosis of cancer | |
| PE20181051A1 (es) | Anticuerpo anti-epha4 | |
| CO6311009A2 (es) | Anticuerpos monoclonales anti-cd151 de origen murino quimericos y humanizados para inhibir el crecimiento tumoral, secuencias de aminoacidos y nucleicos que los codifican, compuestod derivados o fragmentos funcionales y productos y/o composiciones qu |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |